-
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner October 10th, 2019, Bangkok, Thailand — Today, Red Herring announced its Top 100 Asia award winners in recognition of the leading private companies from the region, celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Asia enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1000 privately financed companies each year in the Asia. Since 1996, ...Oct. 15. 2019 -
EOFLOW Chosen as Company of the Year
EOFLOW made it to the 'Top 10 Diabetes Care Solutions Providers - 2019' list and was chosen as the Company of the Year by Medtech Outlook magazine (see the attachment for a reprint). One can read more about it at: https://diabetes-care.medicaltechoutlook.com/vendors/top-diabetes-care-companies.htmlOct. 07. 2019 -
Menarini Diagnostics & EOFlow sign a long term business agreement
EOFlow Co., Ltd. and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of Innovative Insulin Patch Pump Seoul, South Korea and Florence, Italy 17 September 2019 – EOFlow Co., Ltd., developer of novel wearable drug delivery solutions, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the Insulin Patch Pump product developed by EOFlow Co., Ltd. “We are very pleased and excited to work with A. Menarini Diagno...Sep. 17. 2019 -
EOFLOW Receives Breakthrough Device Designation from FDA
EOFlow Receives FDA Breakthrough Device Designation on its Integrated Wearable Automated Insulin Delivery System SAN JOSE, USA and SEOUL, South Korea, March 14, 2019 EOFLOW CO., Ltd., an emerging medical device company with offices in Seoul, South Korea and San Jose, California, announced today that its closed loop Automated Insulin Delivery /Artificial Pancreas Device (AID/AP), the EOPancreas System, has received Breakthrough Device Designation by the U.S. Food and Drug Administration. The EOPancreas System is designed to pr...Mar. 14. 2019 -
JDRF Partners with EOFlow to Develop Wearable Automated Insulin Delivery System for People with Type 1 Diabetes
JDRF Partners with EOFlow to Develop Wearable Automated Insulin Delivery System for People with Type 1 Diabetes —The disposable patch device would be small enough to enable use of wearable artificial pancreas technology on a child— NEW YORK, USA and SEOUL, South Korea, January 25, 2017 — JDRF, the global leading organization funding type 1 diabetes (T1D) research, is pleased to announce a new Industry Development and Discovery Partnership supporting South Korea’s EOFlow Co., Ltd. in the development of a wearable, d...Jan. 28. 2018 -
EOFLOW chosen as the best TIPS company of 2017
EOFLOW was voted the best TIPS-backed company of 2017 at the '2017 TIPS Grand Convention.' The selection was based on weighed scores of votes from a group of investors as well as the convention attendees. TIPS (Tech Incubator Program for Start-up) is a startup incubation program sponsored by Ministry of SME and Startups (MSS), and jointly run by Korea Business Angels Association, private angels & incubator groups. TIPS has been widely considered the best-run incubation program in Korea that it is bei...Dec. 21. 2017 -
EOPatch gets its first regulatory approval
EOPatch, the first wearable disposable insulin pump product from EOFLOW, got its first regulatory approval, from the Korean MFDS (Ministry of Food and Drug Safety). EOFLOW will immediately start preceding clinical trials and plans to launch the product in Korea this coming spring. Earlier, EOFLOW has appointed Huons (www.huons.com) as the exclusive distributor of EOPatch in the Korean market.Dec. 18. 2017 -
EOPatch awarded GD (Good Design) designation
EOFLOW's wearable disposable insulin pump product, EOPatch, was recently awarded the highly selective Good Design (GD) designation. Hosted annually by Korea Institute of Design Promotion (KIDP) and sponsored by the Korean Ministry of Trade, Industry & Energy (MOTIE), the GD Selection is subject to highly competitive selection processes, and the designation is yet another validation of the excellence of the design and usability of EOPatch. The picture below is EOPatch on display during the Sele...Dec. 13. 2017 -
Luis Malave joins as new president of EOFLOW
Mr. Luis Malave, a long-time industry insider who has contributed significantly to the emergence of the smart insulin patch pump industry, has joined EOFLOW as the new president. Luis was one of the earliest employees at Insulet and was the COO of the company at the time he left. He was also an early member of MiniMed. Prior to this, he also worked at Medtronic and University of Minnesota.Oct. 17. 2017 -
Dr. David Klonoff joins as a Scientific Advisory Board member
EOFLOW announces that David Klonoff, M.D. has joined EOFLOW as the latest member of its Scientific Advisory Board. Dr. Klonoff is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. He has been a Principal Investigator on 110 clinical trials of diabetes drugs and devices, and has been lead investigator on multicenter trials for Novo, Sanofi, Diasome, and Medtronic. He was the lead investigator for th...Oct. 16. 2017 -
Dr. Jonathan Woo joins EOFLOW as CSO
EOFLOW announces that Dr. Jonathan Woo has joined the company as the Chief Strategy Officer. Jonathan was the CEO and Co-Founder of Precursor Energetics, where he launched and managed a Silicon-valley venture-funded advanced material-design company in clean-tech area focusing on printable CIGS solar cell, thin-film Li-ion battery, and wearable/flexible thin-film-transistor display products using printed-electronics processes. He was the CTO and Co-Founder of Nanostellar, working in the area of nano-material design and development for auto...Oct. 13. 2017 -
Luis Malave joins as a new board member of EOFLOW
EOFLOW announces that Luis Malave, a long time industry insider, has formally joined as a new board member as of October 1, 2017. Luis was one of the earliest employees at Insulet and was the COO of the company at the time he left. He was also an early member of MiniMed. Prior to this, he also worked at Medtronic and University of Minnesota.Oct. 12. 2017 -
EOFLOW signs up HUONS as distribution partner for Korea
EOFLOW and Huons (www.huons.com) signed an agreement to appoint Huons an exclusive distributor in the Korean market for EOFLOW's disposable wearable insulin pump solution, EOPatch. Huons is one of the fastest growing pharmaceutical companies in Korea. "We are excited that EOPatch will allow many diabetic patients and their families better manage the disease and improve their quality of life," says Mr. Um, Key An, the president of Huons. You can read about more details from other news sites below (in Korean...Sep. 07. 2017 -
EOFLOW sets up a US subsidiary
EOFLOW is announcing the establishment of EOFLOW, INC., a wholly owned subsidiary of EOFLOW Co., Ltd., in the heart of Silicon Valley, San Jose. The new subsidiary will be largely responsible for the global marketing operations of the whole EOFLOW. It is currently manned by some well-experienced and highly respected industry insiders whose names will be released later at opportune times.Sep. 04. 2017
Healthcare Innovation Park #H2102 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
